Cognition Therapeutics is a biotechnology business based in the US. Cognition Therapeutics shares (CGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.45 – an increase of 7.03% over the previous week. Cognition Therapeutics employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.45 |
|---|---|
| 52-week range | $0.31 - $2.95 |
| 50-day moving average | $0.42 |
| 200-day moving average | $0.61 |
| Wall St. target price | $5.40 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.86 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.4458 from 2025-05-02
| 1 week (2025-04-25) | 1.83% |
|---|---|
| 1 month (2025-04-04) | 25.86% |
| 3 months (2025-02-05) | -31.69% |
| 6 months (2024-11-05) | -8.68% |
| 1 year (2024-05-03) | -76.90% |
|---|---|
| 2 years (2023-05-04) | -73.31% |
| 3 years (2022-05-04) | 3.01 |
| 5 years (2020-05-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -103.15% |
| Return on equity TTM | -157.19% |
| Profit margin | 0% |
| Book value | $0.31 |
| Market Capitalization | $27.6 million |
TTM: trailing 12 months
We're not expecting Cognition Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Cognition Therapeutics's shares have ranged in value from as little as $0.3051 up to $2.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cognition Therapeutics's is 1.002. This would suggest that Cognition Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Cognition Therapeutics's beta into context you can compare it against those of similar companies.
Cognition Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York. .
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.